close
close

OPKO Health (NASDAQ:OPK) stock gap has fallen to $1.23


The shares of OPKO Health, Inc. (NASDAQ:OPK – Get Free Report) fell before the market opened on Friday. The stock previously closed at $1.23, but opened at $1.20. OPKO Health shares last traded at $1.24, with a volume of 321,622 shares changing hands.

Wall Street analysts predict growth

A number of brokers have recently expressed their opinions about OPK. Barrington Research reiterated an “outperform” rating and set a $1.50 price target on shares of OPKO Health in a report on Monday, April 1. StockNews.com downgraded shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Friday, March 1st. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of OPKO Health in a report on Wednesday, April 3. Finally, Piper Sandler reiterated an “overweight” rating and set a $5.00 price target on shares of OPKO Health in a report on Monday, April 1.

Get our latest stock report on OPKO Health

OPKO Health Price Performance

The company has a current ratio of 1.55, a quick ratio of 1.22 and a debt-to-equity ratio of 0.15. The company has a market cap of $857.30 million, a price-to-earnings ratio of -4.92 and a beta of 1.82. The company’s 50-day simple moving average is $1.08 and its 200-day simple moving average is $1.23.

OPKO Health (NASDAQ:OPK – Get Free Report) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting analyst consensus estimates of ($0.09). The company had revenue of $181.90 million for the quarter, compared to the consensus estimate of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The company’s revenue fell 1.9% year over year this quarter. In the same quarter last year, the company posted earnings per share of ($0.11). As a group, equity research analysts expect OPKO Health, Inc. will post earnings per share of -0.33 for the current year.

Insider activity at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 500,000 shares of stock in a transaction dated Monday, March 18th. The shares were purchased at an average price of $0.87 per share, with a total value of $435,000.00. Following the transaction, the CEO now directly owns 210,968,225 shares of the company’s stock, valued at $183,542,355.75. The acquisition was disclosed in a filing with the SEC, which can be accessed via this hyperlink. In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were purchased at an average price of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the acquisition, the CEO now directly owns 210,968,225 shares of the company’s stock, valued at approximately $183,542,355.75. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Richard M. Krasno purchased 30,000 shares of stock in a transaction that occurred on Monday, January 29th. The shares were purchased at an average price of $0.99 per share, with a total value of $29,700.00. Following the completion of the purchase, the director now directly owns 103,333 shares in the company, valued at $102,299.67. The explanation for this purchase can be found here. Insiders bought 4,630,000 company shares worth $4,422,700 in the last 90 days. Insiders own 47.26% of the company’s shares.

Institutional inflow and outflow

Hedge funds have recently changed their positions in the company. Vanguard Group Inc. increased its stake in shares of OPKO Health by 1.1% in the 4th quarter. Vanguard Group Inc. now owns 39,751,293 shares of the biotechnology company’s stock worth $60,024,000 after acquiring an additional 428,520 shares during the last quarter. State Street Corp increased its stake in shares of OPKO Health by 56.7% in the first quarter. State Street Corp now owns 27,688,831 shares of the biotechnology company’s stock worth $95,250,000 after purchasing an additional 10,014,088 shares during the period. Geode Capital Management LLC grew its holdings in shares of OPKO Health by 3.9% in the second quarter. Geode Capital Management LLC now owns 8,742,614 shares of the biotechnology company’s stock worth $18,971,000 after purchasing an additional 331,968 shares in the last quarter. Millennium Management LLC grew its holdings in OPKO Health by 318.6% in the second quarter. Millennium Management LLC now owns 7,390,435 shares of the biotechnology company’s stock worth $18,698,000 after acquiring an additional 5,624,866 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in OPKO Health by 73.2% during the first quarter. Dimensional Fund Advisors LP now owns 7,184,414 shares of the biotechnology company’s stock worth $24,717,000 after acquiring an additional 3,037,320 shares in the last quarter. 64.63% of the shares are held by institutional investors and hedge funds.

About OPKO Health

(Get a free report)

OPKO Health, Inc, a healthcare company, engages in diagnostic and pharmaceutical activities in the United States, Ireland, Chile, Spain, Israel, Mexico and internationally. The company’s Diagnostics segment operates BioReference Laboratories that provide laboratory testing services for the detection, diagnosis, evaluation, monitoring and treatment of diseases, including esoteric testing, molecular diagnostics, anatomic pathology, genetics, women’s health and correctional health care to physician practices, clinics , hospitals, employers and government units; and 4Kscore prostate cancer test.

Also see



Receive daily news and reviews for OPKO Health – Enter your email address below to receive a daily summary of the latest news and analyst ratings for OPKO Health and related companies with MarketBeat.com’s FREE daily email newsletter.